Bayer’s Zieler On The Power Of Real World Data, Asia Pacific Outlook

Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, tells Scrip why real world data is “very powerful” as more stakeholders including physicians look beyond just randomized clinical trial data. Zieler also underscores the German multinational’s intent to give “special attention” to the fast-growing Asia Pacific region.

The Asia Pacific (APAC) is a significant contributor to Bayer AG ’s pharmaceutical earnings and Claus Zieler, senior vice president and head of commercial operations, Bayer pharmaceuticals division Asia Pacific, indicates that the German multinational is keen to sustain the momentum in the region. He maintains an upbeat tenor for a basket of products including Xarelto (rivaroxaban) and Eylea (aflibercept), for which Bayer recently ramped up its sales expectations, but prefers not to be drawn into specifics on any potential headwinds in the region as a result of the emerging geopolitical situation.

In an interview with Scrip in Singapore last month, Zieler also underscored the value of real world data in the...